Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers
NCT01291524 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2021-01-22
Summary
The purpose of this study is to 1) evaluate the extent of absorption of a single dose of a pregabalin controlled release (CR) tablet administered a) fasted at bedtime, b) immediately following a 400 to 500 calorie evening meal, and c) immediately following a 600 to 750 calorie evening meal as compared to a single dose of the pregabalin immediate release (IR)capsule, 2) evaluate the safety and tolerability of a single dose of a pregabalin controlled release tablet administered with various caloric sized dinners and at bedtime as compared to a single dose of the pregabalin immediate release capsule.
Conditions
- Healthy
Interventions
- DRUG
-
Pregabalin controlled release, 330 mg, 400 to 500 calorie
A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
- DRUG
-
Pregabalin controlled release, 330 mg, 600- 750 calorie
A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
- DRUG
-
Pregabalin controlled release, 330 mg, bedtime
A single oral dose of 330 mg controlled release tablet administered at bedtime
- DRUG
-
Pregabalin immediate release, 300 mg
A single oral dose of 300 mg immediate release capsule administered in the evening
Sponsors & Collaborators
-
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-02-28
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
Countries
- United States
Study Locations
More Related Trials
-
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule
NCT01202422 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers
NCT01257516 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers
NCT01220219 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule
NCT01202435 ·Status: COMPLETED ·Phase: PHASE1
-
Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects
NCT02103686 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain
NCT00301223 ·Status: COMPLETED ·Phase: PHASE3
-
Pregabalin Peripheral Neuropathic Pain Study
NCT00141219 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of Two Formulation of Pregabalin
NCT03712475 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation
NCT02103647 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers
NCT02725112 ·Status: COMPLETED ·Phase: PHASE1
-
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
NCT01455428 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Pregabalin in Fibromyalgia
NCT00151489 ·Status: COMPLETED ·Phase: PHASE3
-
A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients
NCT00654940 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain
NCT01202227 ·Status: COMPLETED ·Phase: PHASE3
-
Adolescent Fibromyalgia Study
NCT01020474 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety Study Of Pregabalin In Fibromyalgia
NCT00282997 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain
NCT03407430 ·Status: TERMINATED ·Phase: PHASE2
-
An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet
NCT01342198 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg
NCT02955472 ·Status: COMPLETED ·Phase: PHASE1
-
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
NCT00159679 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance
NCT00666939 ·Status: COMPLETED ·Phase: PHASE3
-
Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia
NCT00883740 ·Status: COMPLETED ·Phase: PHASE3
-
Pregabalin In Adolescent Patients With Fibromyalgia
NCT01020526 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553475 ·Status: COMPLETED ·Phase: PHASE3